Trust Co. of Oklahoma purchased a new stake in First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 30,927 shares of the company’s stock, valued at approximately $1,283,000.
A number of other hedge funds have also recently made changes to their positions in the company. Compass Financial Management LLC bought a new position in shares of First Trust Nasdaq Pharmaceuticals ETF in the second quarter worth approximately $29,000. Vivaldi Capital Management LP lifted its position in First Trust Nasdaq Pharmaceuticals ETF by 16.0% during the first quarter. Vivaldi Capital Management LP now owns 12,590 shares of the company’s stock valued at $433,000 after purchasing an additional 1,741 shares during the last quarter. MinichMacGregor Wealth Management LLC bought a new stake in First Trust Nasdaq Pharmaceuticals ETF during the third quarter valued at approximately $968,000. Finally, Nilsine Partners LLC lifted its position in First Trust Nasdaq Pharmaceuticals ETF by 3.5% during the second quarter. Nilsine Partners LLC now owns 28,057 shares of the company’s stock valued at $1,071,000 after purchasing an additional 937 shares during the last quarter.
First Trust Nasdaq Pharmaceuticals ETF Price Performance
FTXH stock traded up $0.94 during midday trading on Thursday, reaching $42.23. The company had a trading volume of 31,859 shares, compared to its average volume of 232,468. First Trust Nasdaq Pharmaceuticals ETF has a 1 year low of $28.85 and a 1 year high of $43.52. The company has a market capitalization of $1.09 billion, a P/E ratio of 14.51 and a beta of 0.45. The firm has a 50-day moving average price of $41.11 and a 200-day moving average price of $37.75.
First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend
The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Thursday, September 24th were given a $0.0113 dividend. This represents a $0.05 annualized dividend and a yield of 0.1%. This is a drop from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.0920. The ex-dividend date was Thursday, September 24th.
First Trust Nasdaq Pharmaceuticals ETF Company Profile
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.
See Also
- Five stocks we like better than First Trust Nasdaq Pharmaceuticals ETF
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
- Fastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure
- Synopsys Signals Confidence With $1B Accelerated Buyback, Analysts Raise Targets
Want to see what other hedge funds are holding FTXH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH – Free Report).
Receive News & Ratings for First Trust Nasdaq Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Trust Nasdaq Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
